机构：[1]Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.[2]Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.[3]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.华中科技大学同济医学院附属同济医院[4]Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China.南方医科大学珠江医院[5]Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.[6]Fudan University Shanghai Cancer Center, Shanghai, China.[7]Henan Provincial People's Hospital, Zhengzhou, Henan, China.[8]West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[9]The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.中山大学附属第一医院[10]The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China.[11]Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.[12]Xuanwu Hospital, Capital Medical University, Beijing, China.首都医科大学宣武医院[13]Fujian Medical University Union Hospital, Fuzhou, Fujian, China.[14]Xiangya Hospital, Central South University, Changsha, Hunan, China.[15]The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.[16]The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.[17]Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.[18]Affiliated Cancer Hospital of Tongji Medical College, Huazhong University of Science and Technology/Hubei Cancer Hospital, Wuhan, Hubei, China.[19]The Second Affiliated Hospital of University of South China, Hengyang, Hunan, China.[20]Changsha Hospital Affiliated to Xiangya School of Medicine, Central South University/Changsha First Hospital, Changsha, Hunan, China.[21]Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University/Zhuzhou Central Hospital, Zhuzhou, Hunan, China.[22]Xiangtan First People's Hospital, Xiangtan, Hunan, China.[23]Chenzhou First People's Hospital, Chenzhou, Hunan, China.[24]Shaoyang Central Hospital, Shaoyang, Hunan, China.[25]Yongzhou Central Hospital, Yongzhou, Hunan, China.[26]Loudi Central Hospital, Loudi, Hunan, China.[27]Zhangjiajie People's Hospital, Zhangjiajie, Hunan, China.[28]Yueyang People's Hospital, Yueyang, Hunan, China.[29]Yueyang Central Hospital, Yueyang, Hunan, China.[30]Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hilar cholangiocarcinoma (hCCA) is a malignant tumor originating from the epithelial cells of the bile ducts, and it is characterized by an aggressive nature, complex surgical management, high mortality, and poor prognosis. Despite recent advances in surgical techniques, medical devices, and related technologies, there remains a pressing need to standardize diagnostic and therapeutic pathways to improve treatment outcomes and extend long-term patient survival. To better integrate and refine these standards, this consensus was reached through a national conference held in Changsha, Hunan Province, involving multidisciplinary experts from various regions across China. This collaborative effort, drawing from various medical facilities and academic organizations nationwide, resulted in the reaching of the "Chinese Multicenter Expert Consensus on the Diagnosis and Treatment of Hilar Cholangiocarcinoma: 2025 Edition" based on current clinical studies and over 40 years of clinical practice experience in managing hCCA. The consensus provides a comprehensive overview of hCCA, including its epidemiological characteristics, diagnostic and screening methods, pathological features, staging and classification systems, and various treatment modalities, while offering specific and actionable recommendations for clinical practice that highlight well-defined indications for surgical, local, and systemic therapies and that emphasize the importance of multidisciplinary approaches to both diagnostic and therapeutic workflows.
基金：
Hunan Provincial Science and Technology Innovation
Leading Talent Fund (2024RC1051); the Huxiang
Young Talent Fund (2024RC3232); the Natural Science
Fund for Outstanding Young Scholars of Hunan
Province (2024JJ2037); Key Projects Sponsored by the
Hunan Provincial People's Hospital Benevolence Fund (KCT202404, RS2022A07); and Projects of the Hunan
Provincial Health Commission of China (Z2023031).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|3 区生物学
小类|3 区生物学
最新[2025]版：
大类|3 区生物学
小类|3 区生物学
第一作者：
第一作者机构：[1]Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Liu Sulai,Jiang Jinqiong,Jian Qian,et al.Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition[J].Bioscience Trends.2025,doi:10.5582/bst.2025.01233.
APA：
Liu Sulai,Jiang Jinqiong,Jian Qian,Liu Yingbin,Huang Zhiyong...&Peng Chuang.(2025).Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition.Bioscience Trends,,
MLA：
Liu Sulai,et al."Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition".Bioscience Trends .(2025)
